TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | MicrobiomeTrials
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-01-13Est. Completion: 2032-08-02
Enrollment target: 181 participants
Locations
Univ of Alabama at Birmingham, Birmingham, Alabama, United States
Uni Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Wichita Urology Group PA, Wichita, Kansas, United States
Duke University Medical Center, Durham, North Carolina, United States
Medical University of South Carolina MUSC, Charleston, South Carolina, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Novartis Investigative Site, Camperdown, New South Wales, Australia
Novartis Investigative Site, Wollongong, New South Wales, Australia
Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil